Intravitreous Ranibizumab (Lucentis) for Radiation Maculopathy

Archives of Ophthalmology
doi 10.1001/archophthalmol.2009.376
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Medical Association (AMA)

Related search

Potential Penetration of Topical Ranibizumab (Lucentis) in the Rabbit Eye

Eye
MedicineArtsSensory SystemsOphthalmologyHumanities
2011English

Ghost Cell Glaucoma After Intravitreous Injection of Ranibizumab in Proliferative Diabetic Retinopathy

BMC Ophthalmology
MedicineOphthalmology
2020English

Response to Ranibizumab Following Tachyphylaxis to Bevacizumab in a Patient With Radiation Maculopathy Following Stereotactic Fractionated Radiotherapy for Optic Nerve Meningioma

Archives of Ophthalmology
2012English

Photodynamic Therapy for Maculopathy Due to Radiation Retinopathy

Eye
MedicineArtsSensory SystemsOphthalmologyHumanities
2004English

Corneal Neovascularization and the Utility of Topical VEGF Inhibition: Ranibizumab (Lucentis) vs Bevacizumab (Avastin)

Ocular Surface
Ophthalmology
2012English

OCT‐A in Radiation Induced Maculopathy

Acta Ophthalmologica
MedicineOphthalmology
2018English

Ranibizumab (Lucentis®) Intravítreo en El Tratamiento De Membrana Neovascular Coroidea Secundaria a Coroidopatía Punctata Interna

Archivos de la Sociedad Espanola de Oftalmologia
Ophthalmology
2010English

Macular Functional Changes in Patients With Neovascular Age-Related Macular Degeneration Receiving Ranibizumab Therapy (Lucentis)

BMC Geriatrics
GerontologyGeriatrics
2010English

Vitrectomy for Myopic Traction Maculopathy

Archives of Ophthalmology
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy